CA3177250A1 — Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
Assigned to Bausch Health Ireland Ltd · Expires 2021-11-11 · 5y expired
What this patent protects
The present disclosure is directed to the use of methylnaltrexone or a salt thereof or an ion pair thereof for reducing mortality in a subject suffering from an underlying disease or condition (e.g., advanced illness, cancer, a chronic non-cancer pain, postoperative ileus, or rec…
USPTO Abstract
The present disclosure is directed to the use of methylnaltrexone or a salt thereof or an ion pair thereof for reducing mortality in a subject suffering from an underlying disease or condition (e.g., advanced illness, cancer, a chronic non-cancer pain, postoperative ileus, or recovery from orthopedic surgery).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.